Brokerages Set Regulus Therapeutics Inc. (NASDAQ:RGLS) Price Target at $7.25

Shares of Regulus Therapeutics Inc. (NASDAQ:RGLS) have earned an average recommendation of “Moderate Buy” from the five research firms that are currently covering the stock, MarketBeat Ratings reports. One research analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have covered the stock in the last year is $7.25.

RGLS has been the topic of a number of analyst reports. SVB Leerink started coverage on shares of Regulus Therapeutics in a research note on Monday, March 18th. They set an “outperform” rating and a $6.00 price objective on the stock. Wells Fargo & Company lifted their price target on shares of Regulus Therapeutics from $2.00 to $3.00 and gave the stock an “equal weight” rating in a research note on Wednesday, March 13th. HC Wainwright reaffirmed a “buy” rating and set a $9.00 price target on shares of Regulus Therapeutics in a research report on Monday. StockNews.com assumed coverage on Regulus Therapeutics in a research note on Tuesday, April 16th. They set a “sell” rating on the stock. Finally, Canaccord Genuity Group lowered their price target on Regulus Therapeutics from $12.00 to $11.00 and set a “buy” rating for the company in a report on Tuesday, March 19th.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Vivo Capital LLC bought a new position in Regulus Therapeutics in the 1st quarter valued at about $14,400,000. FMR LLC boosted its position in shares of Regulus Therapeutics by 32.4% during the 3rd quarter. FMR LLC now owns 2,922,600 shares of the biopharmaceutical company’s stock valued at $4,033,000 after purchasing an additional 716,000 shares in the last quarter. CVI Holdings LLC acquired a new position in shares of Regulus Therapeutics in the 1st quarter worth approximately $4,050,000. Finally, Victory Capital Management Inc. raised its holdings in shares of Regulus Therapeutics by 16.5% in the 4th quarter. Victory Capital Management Inc. now owns 271,736 shares of the biopharmaceutical company’s stock worth $348,000 after purchasing an additional 38,529 shares in the last quarter. Institutional investors own 92.38% of the company’s stock.

Regulus Therapeutics Stock Down 0.9 %

Regulus Therapeutics stock opened at $2.25 on Tuesday. The firm has a market capitalization of $147.29 million, a P/E ratio of -1.42 and a beta of 1.59. The firm has a fifty day moving average of $2.37 and a 200-day moving average of $1.70. Regulus Therapeutics has a 52-week low of $1.08 and a 52-week high of $3.79.

Regulus Therapeutics (NASDAQ:RGLS) last issued its quarterly earnings data on Thursday, March 21st. The biopharmaceutical company reported ($0.40) EPS for the quarter, hitting analysts’ consensus estimates of ($0.40). On average, research analysts expect that Regulus Therapeutics will post -0.52 EPS for the current fiscal year.

About Regulus Therapeutics

Regulus Therapeutics Inc, a clinical stage biopharmaceutical company, focuses on discovery and development of drugs that targets microRNAs to treat a range of diseases in the United States. Its product candidates include RG-012, an anti-miR targeting miR-21 that is in Phase II clinical trial for the treatment of Alport syndrome, a life-threatening kidney disease; and RGLS8429, an anti-miR targeting miR-17, which is in Phase 1b clinical study for the treatment of autosomal dominant polycystic kidney disease.